表观遗传学
生物
染色质
组蛋白
重编程
基因沉默
表观遗传学
转录因子
DNA甲基化
表观遗传疗法
癌症研究
神经科学
后生
细胞生物学
染色质免疫沉淀
免疫系统
组蛋白H3
遗传学
计算生物学
染色质重塑
生物信息学
作者
Angela Liou,Praveen Raju,Peter D. Adams
标识
DOI:10.1080/14728222.2026.2762560
摘要
INTRODUCTION: Pediatric diffuse midline glioma (DMG) is a near-lethal childhood brain tumor. The lysine-to-methionine substitution at histone H3 lysine (K) 27 disrupts normal histone post-translational modification, driving global loss of H3K27 trimethylation and widespread reprogramming of chromatin accessibility and transcription that sustain oncogenic cell states. AREAS COVERED: In this review, we synthesize current knowledge on how histone modifications, DNA methylation, and chromatin-remodeling machinery are altered in H3K27M DMG, and summarize therapeutic strategies aimed at targeting each affected epigenetic regulator. We also highlight an emerging therapeutic paradigm in which epigenetic disruption of repetitive-element silencing may create a viral-mimicry vulnerability that can be therapeutically exploited. EXPERT OPINION: In our view, viral mimicry represents a promising and potentially powerful therapeutic strategy in H3K27M DMG that exploits an epigenetic vulnerability. Loss of H3K27me3 may weaken repetitive element silencing, likely leaving tumor cells dependent on alternative repressive mechanisms. Disrupting these silencing pathways with epigenetic drug combinations may derepress retrotransposons and activate antiviral sensing, potentially reducing tumor fitness through cell-intrinsic stress and antitumor immune responses. However, clinical translation will require ongoing rigorous preclinical validation, CNS-penetrant agents, biomarkers of epigenetic vulnerability, and resistance monitoring. Future studies must also thoughtfully balance antitumor immunity against neuroinflammatory toxicity.
科研通智能强力驱动
Strongly Powered by AbleSci AI